Overview

An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC

Status:
Not yet recruiting

Trial end date:
2028-12-31

Target enrollment:

Participant gender:

Summary

The treatment of distant metastasis is a key challenge for nasopharyngeal carcinoma because of poor outcomes, among which, chemotherapy is the cornerstone. However, many studies reported the use of different chemotherapy regimens to prolong the survival of metastatic nasopharyngeal carcinoma, while few of them focused on how to reduce the side effects of chemotherapy or improve the life quality of patients. Blocking the immune checkpoint is one of the effective strategies of tumor immunotherapy. Thus, we sought to find a proper chemotherapy regimen combined with PD-1 antibody JS001.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Sun Yat-sen University

Collaborator:

Shanghai Junshi Bioscience Co., Ltd.

Treatments:

Fluorouracil
Gemcitabine